⌕
Novo Nordisk · NVO · NYSE
Tenet 62 · Solid
Compare
$40.70−2.16%At closeTenet 62 · Solid
$40.70−0.90 (−2.16%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$40.12−0.58 (−1.43%)
After hours: Nov 17, 2026, 7:57 PM ET

Novo Nordisk (NVO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~22.7%/yr (FY21→FY25), net margin 33.1%; free cash flow runs at 73% of net income. Check the accrual gap.
The four lines that matter · FY21–FY25
Revenue ($B)▲20.5%
48.6
FY21→FY25CAGR +22.7%/yr
Net income ($B)▲14.8%
16.1
FY21→FY25CAGR +22.0%/yr
Free cash flow ($B)▼24.4%
11.7
FY21→FY25CAGR +9.2%/yr
Diluted EPS▲15.2%
3.62
buyback-liftedCAGR −23.1%/yr
What the receipts whisper · what a headline number hides
Share count
−100.0%

2280.0tn → 0.0tn diluted shares since FY22. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$9.5B

+44.4% YoY in FY25 · 19.5% of revenue.

Returns vs FCF
71%

$8.4B returned vs $11.7B of FCF in FY25. Buybacks + dividends covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)48.6Revenue−9.2COGS39.3Gross profit−8.2R&D−11.0SG&A20.1Op income−4.0Tax & other16.1Net income

33¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 83.2% → 81.0%. Net margin 33.1% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
48,564.448,564.440,308.034,466.225,455.921,429.4▲20.5%+22.7%
Cost of revenue
9,237.69,237.66,179.75,307.34,092.43,600.7▲49.5%+26.6%
Gross profit
39,326.839,326.834,128.329,158.921,363.517,828.7▲15.2%+21.9%
Research & development
8,177.18,177.16,671.04,814.43,459.32,704.9▲22.6%+31.9%
Selling, general & admin
11,043.211,043.29,351.99,140.87,291.26,248.9▲18.1%+15.3%
Total operating expenses
19,267.419,267.416,314.913,937.510,601.78,903.3▲18.1%+21.3%
Operating incomefeeds ROC rank
20,059.420,059.417,813.515,221.410,761.78,925.5▲12.6%+22.4%
Other income, net
452.9452.9−159.3311.6−826.766.4——
Pretax income
20,512.320,512.317,654.115,533.09,935.08,991.8▲16.2%+22.9%
Income tax
4,416.44,416.43,637.03,114.91,947.41,723.3▲21.4%+26.5%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
16,095.916,095.914,017.212,418.17,987.67,268.5▲14.8%+22.0%
Per share
Diluted EPSbuyback-sensitive
3.623.623.142.761.7610.37▲15.2%−23.1%
Diluted shares (tn)
0.000.000.000.002,280.000.00▲0.0%+17.9%
Margins
Gross margin75th pct in Healthcare
81.0%81.0%84.7%84.6%83.9%83.2%▼3.7pp−2.2pp
Operating margin
41.3%41.3%44.2%44.2%42.3%41.7%▼2.9pp−0.3pp
Net margin96th pct in Healthcare
33.1%33.1%34.8%36.0%31.4%33.9%▼1.6pp−0.8pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-04 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Novo Nordisk's revenue last fiscal year?

Novo Nordisk reported revenue of $48.6B in fiscal 2025, up 20.5% from fiscal 2024.

What was Novo Nordisk's net income?

Novo Nordisk reported net income of $16.1B in fiscal 2025, a net margin of 33.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.